-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer, the second largest cancer among men in the world after lung cancer, is one of the leading causes of cancer death.
previous studies have shown that higher concentrations of IGF-1 (insulin-like growth factor-I) in the body correspond to a higher risk of prostate cancer, while obesity is associated with a higher risk of invasive disease.
, low levels of testosterone can reduce the risk of prostate cancer.
the pathogenesis of prostate cancer is not yet known, it is particularly important to identify new risk factors for the disease.
the study aims to identify new factors affecting prostate cancer morbidity and mortality in the UK Biobank.
researchers collected as many as 211,754 male baseline blood samples and subseeds from five years later, and measured a range of biomarkers associated with cardiovascular, bone, joint, diabetes, kidney and liver.
follow-up of participants through a health management data set to identify cases of prostate cancer.
-related markers detected a higher risk than the researchers found that after an average follow-up time of 6.9 years, a total of 5,763 cases of prostate cancer and 331 deaths from prostate cancer were identified.
studies have shown that the occurrence of prostate cancer is positively related to the concentration of vitamin D, urea and phosphate in the body's circulation, and negatively related to glucose, total protein, and tyrosine transaminase.
phosphate and cystatin-C (cysteine protease inhibitor-C) were the only positive and reverse biomarkers, respectively, and were associated with the risk of onset in follow-up (excluding the previous 4 years).
there is currently no evidence of factors associated with prostate cancer deaths.
, the study found several new biomarkers associated with the incidence of prostate cancer and provided a basis for future research into the disease.
.